signaling. Our integrated multi-omics analysis unexpectedly revealed an exposome-related mutational signature to be associated with EEEC leading to EEEC specific CTNNB1 and SIGLEC10 hotspot mutations and downstream protein pathway disturbance. Interestingly, in EEECs SIGLEC10 Q144K mutation resulted in aberrant Siglec-10 protein expression and promoted progestin resistance by interacting with ERα. We identified and validated four (EEF1E1, ILVBL, SRPK1 and NUDT5) biomarkers of progestin resistance. 

Conclusion/Implications Our study provides a unique high-quality proteogenomic resource of EEECs, and explicates the distinct clinical and molecular characteristics of EEECs, encompassing obesity, genetic susceptibility, and environmental exposure, that are concomitant with pathogenesis and progestin resistance. Furthermore, we identified biomarkers for progestin response in EEEC fertility-sparing treatment. These attributes can be utilized to promote primary prevention and early detection of EEECs.

**PRO026/#185**

**PROTEOGENOMICS DECIPHER DISTINCT METASTASIS PATTERNS AND BIOMARKERS OF ENDOMETRIAL CARCINOMA**

Gang Chen*, Zhe Hu, Zimeng Wu, Chuanyang Sun, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Clinical Research Center for Gynecology and Obstetrics, Wuhan, China

10.1136/ijgc-2023-IGCS.68

**Introduction** Endometrial carcinoma is a common gynecologic malignancy, and lymph node metastasis greatly affects patient outcomes. Proteogenomics analysis has emerged as a powerful tool for identifying molecular mechanisms involved in cancer progression and metastasis, offering potential for biomarkers discovery and personalized treatment strategies.

**Methods** In this study, we utilized WES, proteomics, and multiplex immunohistochemistry to investigate the metastasis patterns of different molecular subtypes in a cohort of 96 EC patients with lymph-node metastasis and 126 without metastasis. Our aim was to elucidate the molecular characteristics that distinguish between these two groups and identify potential biomarkers for metastasis.

**Results** Proteogenomics analysis identified two distinct metastasis patterns of EC associated with TME. One pattern is characterized by an immune-cold phenotype, which is predominantly observed in patients with the MSI subtype. These patients often exhibit JAK1 mutations, defects in immunoproteasome components and HLA complexes, leading to deficiencies in antigen presentation pathways, resulting in immune evasion. The other is characterized by an immune-hot phenotype, mainly distributed in the CNL and few MSI subtype, with significant infiltration of macrophages and upregulation of integrin pathways, promoting tumor cells to undergo mesenchymal transition. Additionally, we explored and validated three consensus biomarkers shared across different molecular subtypes for predicting lymph-node metastasis.

**Conclusion/Implications** Our research provides an unprecedented large-scale multi-omics resource of lymphatic metastasis EC, offering novel insights and new biomarkers for effectively stratifying high-risk patients for lymphatic metastasis. We have deciphered two distinct metastasis patterns in EC, which can be exploited for the development of personalized screening and targeting strategies.

**PRO027/#815**

**CLINICAL IMPACT OF ULTRASTAGING OF SENTINEL LYMPH NODE MAPPING WITH INDOCYANINE GREEN INJECTION IN PATIENTS WITH ENDOMETRIAL CANCER**

1,2Sang Hyun Cho*, 1Hyun Min Kim, 1Sang Wun Kim. 1St. Vincent’s Hospital, The Catholic University of Korea, Obstetrics and Gynecology, Suwon, Korea, Republic of; 2Graduate School, Yonsei University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of; 3Yongin Severance Hospital, Yonsei University College of Medicine, Pathology, Yongin, Korea, Republic of; 4Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of

10.1136/ijgc-2023-IGCS.69

**Introduction** This retrospective study aimed to confirm the clinical impact of ultrastaging of sentinel lymph node (SLN) mapping with Indocyanine green (ICG) injection in patients with endometrial cancer (EC).

**Methods** This retrospective study obtained data from the electronic medical records of Severance Hospital. The subjects included patients with EC who have undergone surgical staging with SLN mapping using ICG injection between June 2014 to December 2017 at Severance Hospital. The SLN paraffin blocks were sliced into two or three layers at an interval of 200 μm between the layers by 3 μm thickness. The immunohistochemistry was performed with anti-cytokeratin antibodies AE1/AE3.

**Results** A total of 138 patients included (no metastasis (NM), n=124, 89.9%; macro-metastasis (MAC), n=2, 1.4%; micro-metastasis (MM), n=11, 8.0%; isolated tumor cells (ITC), n=1, 0.7%). A total of 1006 paraffin blocks were examined (NM, n=984, 97.8%; MAC, n=2, 0.2%; MM, n=13, 1.3%; ITC, n=7, 0.7%). The 5-year disease-free survival significantly differed according to the results of ultrastaging (NM, 94.9%; MAC and MM, 69.2%; p<0.001). The 5-year overall survival was no significant difference in the status of ultrastaging (NM, 97.4%; MAC and MM, 100%; p=0.579). Analyzing the Cox proportional hazards model, the prognostic factor of recurrence was ultrastaging (Hazard Ratio 5.70, [95% Confidence Interval 1.50–21.68], p=0.011). The ultrastaging had no prognostic impact on the overall survival.

**Conclusion/Implications** The ultrastaging detected more MAC, MM, and ITC of SLN and was a prognostic factor of recurrence in patients with EC. Further study is needed for the clinical impact of ultrastaging for adjuvant therapy of EC.

**PRO028/#496**

**THE EFFICACY OF METFORMIN IN MEGESTROL ACETATE-BASED FERTILITY-SPARING TREATMENT FOR PATIENTS WITH ENDOMETRIAL ATYPICAL HYPERPLASIA AND ENDOMETRIAL CANCER: LONG-TERM OUTCOMES OF A RANDOMISED CONTROLLED TRIAL**

Youting Dong*. Shanghai Medical College, Fudan University, Shanghai, Shanghai Medical College, Shanghai, China

10.1136/ijgc-2023-IGCS.70

**Introduction** To assess the long-term efficacy of metformin in megestrol acetate (MA)-based fertility-sparing treatment for patients with endometrial atypical hyperplasia (EAH) and endometrioid endometrial cancer (EEC).

**Methods** Patients with EAH or EEC were firstly stratified, then randomised to receive MA (160 mg orally, daily) or MA
ROBOT-ASSISTED VERSUS CONVENTIONAL LAPAROSCOPIC SURGERY FOR ENDOMETRIAL CANCER: LONG-TERM COMPARISON OF OUTCOMES

Pyo Lee, Yong Tae Kim, Young Tae Lee, Hyun Young Kim, Hyun-Jae Park, and Jiheum Paek

Introduction There is a lack of multi-institutional large-volume and long-term follow-up data on comparisons between robot-assisted surgery and conventional laparoscopic surgery. This study compared the surgical and long-term survival outcomes between patients who underwent robot-assisted or conventional laparoscopic surgery for endometrial cancer.

Methods We retrospectively reviewed the data of patients from five large academic institutions who underwent either robot-assisted or conventional laparoscopic surgery for endometrial cancer. This study compared the surgical and long-term survival outcomes between patients who underwent robot-assisted or conventional laparoscopic surgery for endometrial cancer.

Results The study cohort included 1,003 unselected patients: 551 and 452 patients received conventional laparoscopic and robot-assisted surgery, respectively. The median follow-up duration was 57 months. Postoperative complications were significantly less likely to occur in the robot-assisted surgery group than in the laparoscopic surgery group (7.74% vs. 13.79%, P = 0.002). There were no significant differences in survival: 5-year disease-free survival was 91.2% versus 90.0% (P = 0.628) and overall survival was 97.9% versus 96.8% (P = 0.285) in the robot-assisted and laparoscopic surgery cohorts, respectively. Cox proportional hazard regression models demonstrated that the mode of surgery was not associated with disease-free survival (hazard ratio, 0.897; confidence interval, 0.563–1.429) or overall survival (hazard ratio, 0.791; confidence interval, 0.330–1.895) after adjusting for confounding factors.

Conclusion/Implications Robot-assisted surgery for endometrial cancer is associated with similar long-term survival outcomes but fewer postoperative complications as compared to conventional laparoscopic surgery.

A PREDICTIVE MODEL FOR LYMPH NODE METASTASIS USING A TUMOR LOCATION IN PRESUMED EARLY-STAGE ENDOMETRIOD ENDOMETRIAL CANCER PATIENTS

Tae-Wook Kong, Jinmin Lee, Jeeyeon Kim*, Joo-Hyuk Son, Suk-Joon Chang

Introduction In our institution, we have noted that the location of the tumor is an important factor in predicting lymph node metastasis in presumed early-stage endometrioid endometrial cancer patients. We developed a predictive model for lymph node metastasis using a tumor location in presumed early-stage endometrioid endometrial cancer patients.

Methods We retrospectively reviewed the medical records of 186 patients who underwent hysterectomy for presumed early-stage endometrioid endometrial cancer. We developed a predictive model for lymph node metastasis using a tumor location.

Results The predictive model for lymph node metastasis was developed using a tumor location. The model showed that the location of the tumor is an important factor in predicting lymph node metastasis. The accuracy of the model was evaluated using receiver operating characteristic (ROC) analysis, which showed a good diagnostic performance.

Conclusion/Implications The location of the tumor is a significant factor in predicting lymph node metastasis in presumed early-stage endometrioid endometrial cancer patients. The developed predictive model can be used to predict lymph node metastasis and guide treatment.